β-Secretase inhibition for the treatment of Alzheimer's disease - Promise and challenge

Trends in Pharmacological Sciences

Volumn 25, Issue 2, 2004, Pages 92-97

  Citron, Martin ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BETA SECRETASE; BETA SECRETASE INHIBITOR; COMPLEMENT; CYTOKINE; MEMBRANE PROTEIN; PHOSPHATASE; PHOSPHOTRANSFERASE;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ASTROCYTE; CELL ACTIVATION; CELL DEATH; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME ISOLATION; HUMAN; MICROGLIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEINASE INHIBITION; REVIEW; TARGET CELL; TREATMENT INDICATION;

EID: 0842309491     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.12.004     Document Type: Review

References (49)

1. Davis K.L., Samuels S.C. Dementia and delirium. Enna S.J., Coyle J.T. Pharmacological Management of Neurological and Psychiatric Disorders. 1998;267-316 McGraw-Hill.
2. Palmer A.M. Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci. 23:2002;426-433.
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
4. Joachim C.L., Selkoe D.J. The seminal role of β-amyloid in the pathogenesis of Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 6:1992;7-34.
5. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 32:2001;181-184.
6. Younkin S.G. The role of A beta 42 in Alzheimer's disease. J. Physiol. (Paris). 92:1998;289-292.
7. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
8. Leung D., et al. Protease inhibitors: current status and future prospects. J. Med. Chem. 43:2000;305-341.
9. Dovey H.F., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76:2001;173-181.
10. Beher D., et al. Pharmacological knock-down of the presenilin 1 heterodimer by a novel γ-secretase inhibitor. J. Biol. Chem. 276:2001;45394-45402.
11. Dash C., et al. Aspartic peptidase inhibitors: implications in drug development. Crit. Rev. Biochem. Mol. Biol. 38:2003;89-119.
12. Tian, G. et al. The mechanism of γ-secretase. Multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J. Biol. Chem. (in press).
13. Lanz T.A., et al. The γ-secretase inhibitor N-[N-(3,5- difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque bearing) Tg2576 mice. J. Pharmacol. Exp. Ther. 305:2003;864-871.
14. Evin G., et al. Alzheimer's disease amyloid precursor protein (AβPP): proteolytic processing, secretases and βA4 amyloid production amyloid. Amyloid: Int. J. Exp. Clin. Invest. 1:1994;263-280.
15. Vassar R., et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:1999;735-741.
16. Sinha S., et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature. 402:1999;537-540.
17. Yan R., et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase specificity. Nature. 402:1999;533-537.
18. Hussain I., et al. Identification of a novel aspartic protease (Asp2) as β-secretase. Mol. Cell. Neurosci. 14:1999;419-427.
19. Saunders A.J., et al. BACE maps to chromosome 11 and a BACE homolog, BACE2, resides in the obligate Down syndrome region of chromosome 21. Science. 286:1999;1255.
20. Sisodia S.S., St George-Hyslop P.H. γ-secretase, Notch, Aβ and Alzheimer's disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3:2002;281-290.
21. Haass C., Steiner H. Alzheimer disease γ-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol. 12:2002;556-562.
22. DeStrooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron. 38:2003;9-12.
23. Li Y.-M., et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 405:2000;689-694.
24. Weggen S., et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
25. Bodendorf U., et al. A splice variant of β-secretase deficient in the amyloidogenic processing of the amyloid precursor protein. J. Biol. Chem. 276:2001;12019-12023.
26. Andrau D., et al. BACE1- and BACE2-expressing human cells. J. Biol. Chem. 278:2003;25859-25866.
27. Holsinger R.M.D., et al. Increased expression of the amyloid precursor β-secretase in sporadic Alzheimer's disease. Ann. Neurol. 51:2002;783-786.
28. Fukumoto H., et al. β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59:2002;1381-1389.
29. Yang L.B., et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9:2003;3-4.
30. Bennett B.D., et al. Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. 275:2000;20647-20651.
31. Hussain I., et al. Asp1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol. Cell. Neurosci. 16:2000;609-619.
32. Farzan M., et al. BACE2, a β-secretase homolog, cleaves at the β-site and within the amyloid-β region of the amyloid-β precursor protein. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9712-9717.
33. Basi G., et al. Antagonistic effects of β-site amyloid precursor protein-cleaving enzymes 1 and 2 on Aβ production in cells. J. Biol. Chem. 278:2003;31512-31520.
34. Bodendorf U., et al. Expression of human β-secretase in the mouse brain increases the steady-state level of β-amyloid. J. Neurochem. 80:2002;799-806.
35. Kamenetz F., et al. APP processing and synaptic function. Neuron. 37:2003;925-937.
36. Luo Y., et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. 4:2001;231-232.
37. Cai H., et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4:2001;233-234.
38. Roberds S.L., et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10:2001;1317-1324.
39. Turner R.T., et al. Subsite specificity of memapsin 2 (β-secretase): implications for inhibitor design. Biochemistry. 40:2001;10001-10006.
40. Kitazume S., et al. Alzheimer's β-secretase, β-site amyloid precursor protein cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13554-13559.
41. Kitazume S., et al. Characterization of α2,6-sialyltransferase cleavage by Alzheimer's β-secretase (BACE1). J. Biol. Chem. 278:2003;14865-14871.
42. Lichtenthaler S., et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278:2003;48713-48719.
43. Luo Y., et al. BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol. Dis. 14:2003;81-88.
44. Harper A.J., et al. Unexpected phenotype in BACE1 mice. Society for Neuroscience (Abstr.). 2002;687.10.
45. Fisher N.D., Hollenberg N.K. Is there a future for renin inhibitors? Expert Opin. Investig. Drugs. 10:2001;417-426.
46. Hong L., et al. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science. 290:2000;150-153.
47. Ghosh A.K., et al. Structure-based design: potent inhibitors of human brain memapsin 2 (β-secretase). J. Med. Chem. 44:2001;2865-2868.
48. Hom R.K., et al. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human β-secretase. J. Med. Chem. 46:2003;1799-1802.
49. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:1991;383-388.